GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (NAS:CAPR) » Definitions » Cyclically Adjusted FCF per Share

Capricor Therapeutics (Capricor Therapeutics) Cyclically Adjusted FCF per Share : $-3.67 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Capricor Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Capricor Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.401. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-3.67 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 35.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 38.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 30.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Capricor Therapeutics was 41.90% per year. The lowest was -4.90% per year. And the median was 25.20% per year.

As of today (2024-04-30), Capricor Therapeutics's current stock price is $5.33. Capricor Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-3.67. Capricor Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Capricor Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Capricor Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Cyclically Adjusted FCF per Share Chart

Capricor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.49 -13.72 -6.95 -4.21 -3.67

Capricor Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.21 -4.12 -4.12 -3.61 -3.67

Competitive Comparison of Capricor Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Capricor Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Capricor Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Capricor Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.401/129.4194*129.4194
=-0.401

Current CPI (Dec. 2023) = 129.4194.

Capricor Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 9.624 99.695 12.493
201406 -5.186 100.560 -6.674
201409 -1.925 100.428 -2.481
201412 -1.846 99.070 -2.412
201503 -1.405 99.621 -1.825
201506 -1.172 100.684 -1.506
201509 -2.051 100.392 -2.644
201512 -2.244 99.792 -2.910
201603 -2.556 100.470 -3.292
201606 -2.739 101.688 -3.486
201609 -1.051 101.861 -1.335
201612 -1.673 101.863 -2.126
201703 -2.186 102.862 -2.750
201706 -1.676 103.349 -2.099
201709 -1.371 104.136 -1.704
201712 -1.015 104.011 -1.263
201803 -1.339 105.290 -1.646
201806 -1.271 106.317 -1.547
201809 -1.022 106.507 -1.242
201812 -1.209 105.998 -1.476
201903 -0.480 107.251 -0.579
201906 -0.514 108.070 -0.616
201909 -0.441 108.329 -0.527
201912 -0.411 108.420 -0.491
202003 -0.177 108.902 -0.210
202006 -0.133 108.767 -0.158
202009 -0.150 109.815 -0.177
202012 -0.188 109.897 -0.221
202103 -0.151 111.754 -0.175
202106 -0.212 114.631 -0.239
202109 -0.165 115.734 -0.185
202112 -0.248 117.630 -0.273
202203 0.965 121.301 1.030
202206 -0.286 125.017 -0.296
202209 -0.278 125.227 -0.287
202212 -0.323 125.222 -0.334
202303 0.149 127.348 0.151
202306 -0.381 128.729 -0.383
202309 -0.365 129.860 -0.364
202312 -0.401 129.419 -0.401

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Capricor Therapeutics  (NAS:CAPR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Capricor Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Capricor Therapeutics (Capricor Therapeutics) Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Executives
David B Musket director C/O CONOR MEDSYSTEMS, INC., 1003 HAMILTON COURT, MENLO PARK CA 94025
Collier Earl M Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paul Gisbert Auwaerter director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Mike Kelliher director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Philip J Gotwals director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Xavier Avat officer: CHIEF BUSINESS OFFICER 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Karimah Es Sabar director C/O 8840 WILSHIRE BOULEVARD, 2ND FLOOR, BEVERLY HILLS CA 90211
Linda Marban director, officer: CHIEF EXECUTIVE OFFICER C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Dunbar George W Jr director C/O COMPETITIVE TECHNOLOGIES, INC., 777 COMMERCE DRIVE, SUITE 100, FAIRFIELD CT 06825
Karen Krasney officer: EVP, GENERAL COUNSEL C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Anthony Bergmann officer: CHIEF FINANCIAL OFFICER C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Louis Manzo director C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Cedars Sinai Medical Center 10 percent owner 8700 BEVERLY BLVD, LOS ANGELES CA 90048-1865
St. John Edward A. 10 percent owner 2560 LORD BALTIMORE DRIVE, BALTIMORE MD 21244
Leland Gershell officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306, NEW YORK NY 10022

Capricor Therapeutics (Capricor Therapeutics) Headlines

From GuruFocus

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

By GuruFocusNews GuruFocusNews 07-04-2022